| PFE |
Pfizer Inc. |
90%
|
Reciprocal relationship from PFE graph: Reciprocal relationship from ARVN graph: Revenue for the quarter is related to the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer and the collabor… |
| PFE |
Pfizer Inc. |
90%
|
Revenue for the quarter is related to the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer and the collaboration and license agreement with Pfizer. |
| RIGEL-PHARMACEUTICALS-INC |
RIGEL-PHARMACEUTICALS-INC |
85%
|
Entered into a license agreement with Rigel Pharmaceuticals, Inc. for the for the exclusive global development, manufacturing, and commercialization rights for VEPPANU. |
| ARVINAS-ESTROGEN-RECEPTOR-INC |
ARVINAS-ESTROGEN-RECEPTOR-INC |
62%
|
business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we continue to conduct our ongoing clinical trials of ARV-10… |
| ARVINAS-OPERATIONS-INC |
ARVINAS-OPERATIONS-INC |
62%
|
otential to be developed as a monotherapy and in combination with chemotherapy in pancreatic ductal adenocarcinoma and in combination with standard of care ("SOC") treatments in colorectal and non-sm… |
| ARVINAS-OPERATIONS-INC-ARVINAS-ANDROGEN-RECEPTOR |
ARVINAS-OPERATIONS-INC-ARVINAS-ANDROGEN-RECEPTOR |
62%
|
business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we continue to conduct our ongoing clinical trials of ARV-10… |
| ARVINAS-WINCHESTER-INC |
ARVINAS-WINCHESTER-INC |
62%
|
business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we continue to conduct our ongoing clinical trials of ARV-10… |
| BAYER-AG |
BAYER-AG |
62%
|
ch 31, 2026 and 2025, respectively. Other Income Other income totaled $6.3 million for the three months ended March 31, 2026, compared to $11.7 million for the three months ended March 31, 2025. The … |
| CARRICK-THERAPEUTICS-INC |
CARRICK-THERAPEUTICS-INC |
62%
|
. The chief operating decision maker evaluates the performance of the operating segment and allocates resources based on net income/loss that also is reported on the consolidated income statement as … |
| F-HOFFMAN-LA-ROCHE-LTD |
F-HOFFMAN-LA-ROCHE-LTD |
62%
|
. The chief operating decision maker evaluates the performance of the operating segment and allocates resources based on net income/loss that also is reported on the consolidated income statement as … |
| NOVARTIS-PHARMA-AG |
NOVARTIS-PHARMA-AG |
62%
|
. The chief operating decision maker evaluates the performance of the operating segment and allocates resources based on net income/loss that also is reported on the consolidated income statement as … |
| NVS |
Novartis AG |
62%
|
Reciprocal relationship from NVS graph: Reciprocal relationship from ARVN graph: Reciprocal relationship from NVS graph: Reciprocal relationship from ARVN graph: Reciprocal relationship from NVS grap… |
| PHARMA-AG |
PHARMA-AG |
62%
|
. We believe the existing cash, cash equivalents and marketable securities on hand will be sufficient to fund our operations into the second half of 2028, which will enable us to execute on multiple … |
| VEPPANU-PFIZER-RESEARCH-CO |
VEPPANU-PFIZER-RESEARCH-CO |
62%
|
. We believe the existing cash, cash equivalents and marketable securities on hand will be sufficient to fund our operations into the second half of 2028, which will enable us to execute on multiple … |
